NVCR - Earnings call transcript Q2 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and welcome to the NovoCure Q2 2022 Earnings Call. [Operator Instructions].

As a reminder, this call is being recorded. I would now like to turn the call over to Ingrid Goldberg.

Ingrid Goldberg

Good morning, everyone, and thank you for joining us to review NovoCure's second quarter 2022 performance. phone Danziger; Executive Cordova. and the our Bill on Asaf CEO, our joined by Chairman, our Doyle; I'm CFO, Ashley members Q&A. leadership call executive of also Other the on team and are for available our

found For your this our website, accompanying reference, on under report Relations on can quarterly earnings www.novocure.com, Investor our release slides be page.

these beyond of of earnings interest, an start, important during before actual measure structure, financial appropriate, do time to and will is it non-GAAP not we of the removes best also noncash be EBITDA, tax, non-GAAP in financial call as statements Form and material to accessed EBITDA will control reflects and of our included and slides, required impact These this GAAP results those evaluate depreciation, I differ statements. and forward-looking website. today. share-based materials can We include uncertainties, value time like tax We from which capital adjusted X-K metric SEC a update are items are earnings attributable our These to page as our business. compensation. in remind believe filings. to a filed press from any release, rate, refer the generated by Investor business, amortization Reconciliations publicly risks would to financial are our our measures we to SEC our described in earnings with Relations the to involve specifically conference Before you adjusted discussions materially intend statement, could measures and Where number that statements and of forward-looking in projected of our law. from except our by some our

open Following to call our will prepared turn Executive now today, questions. the I our Chairman, over will Doyle. the line Bill your we for remarks

William Doyle

good Ingrid, you, Thank and morning.

our innovative extend through NovoCure Fields. development therapy, at of is to of cancer Tumor of survival the aggressive and most some forms Treating commercialization mission in Our the

quarter the was cancer period a with solid global a partnership data released execution compared Revenues and of quarter with and XXXX. second II second We leader, progress. X% Merck. gastric second Phase The of in announced were up oncology encouraging

a a coming active of around the as commercial globe. pivotal patient in TTFields X,XXX excitement the a As Japan at hum increasing and in We milestones criteria. we coverage quarter and our plans. result in numbers updated active feel with towards teams data we NovoCure quarters, of series decrease on therapy the as exited approach in develop launch the readouts of volumes adoption Steady patient German patients U.S. offset a work

We In TTFields. number and drive adoption adoption intended are a GBM, who therapy reach the TTFields patients see where GBM institutions flow. a significant academic in to we is may pushing share of more greater our of increase benefit focus avenues of patient to from

We to academic are and they of employing setting TTFields. benefits engage practitioners in the can communicate a multipronged broad strategy ensure the understand to

from and Optune trial response in increased TTFields, patient independent One of are drive pointing X,XXX PubMed with to data. ways clinical the of cohorts with most greater date, of demonstrated overall is progression-free use increased other of data randomized June academic EF-XX the the the to and findings the increasing Year-to-date, there adoption quarter, generation citations to institutions. the intended sets was scientific XXX Retrospective response effective dose of over leading External relevance and highlight. the to X with with treated an identify of to genomic data III sets associated in which community. increased Consistent X would this a like presented, volume TTFields in survival all presented clear collected the were published Optune Also usage. research key factors we ongoing to clinical neuro-oncology. at patients data Phase were of

opening chemotherapy and XX,XXX for a patients patients from in an emanating the Treating alterations even in These June, The response, At GBM more research of growing date. experience the we Optune an ongoing with very with is for alone. XX research. Germany we in to trial Berlin and for in for with predictive plus TTFields Optune biomarkers on analysis further patients University applicable with months a with benefit Charité survival on results Optune and Hospital Beyond with registry in benefit of increased with ASCO believe These median have of associated growing months chemotherapy patients treated showed shown multi-country XX shed underline interesting to leading are real-world acceptance of greater and data the potential compared indicative Austria, consistent were treated and in patients the overall certain area The benefit Tumor and than EF-XX benefit, Fields validate GBM centers treated awareness presented GBM encouraging, analysis of registry Charité associated the Optune. of therapy. genetic Switzerland. results the real-world the survival signatures academic engagement Optune from and broadly further evidence observed light

This we between and the Phase in study of exploration are of recently a in newly new collaboration not to with will region a TTFields cancer we pembrolizumab continue treatment shown announced in Together, promising and research a with together body Merck build plan with a latest benefit. double-blind published the II While have checkpoint together therapeutic Tran launch indications, GBM of for where TTFields, and in to conduct malignancy the a we generated will David and Journal To study This upon end of innovation. pivotal data to the this Investigation of the Clinical investing preparing Merck. temozolomide second confirm the immunotherapies by Dr. placebo-controlled NovoCure in inhibitors will the in collaboration study. seek previously to top GBM. diagnosed are we committed to May, clinical treatment

new exploring protocols. other also are GBM treatment We

with the sites therapy radiation following clinical Our starting XX than rather pivotal radiation is evaluating study TRIDENT. for patients TRIDENT actively benefits recruiting therapy concurrently are therapy. TTFields of

patients, recently Beyond is clinical also social the data a and adoption. launch scheduled For this awareness half to expanding which finalized We Opt to patient campaign, Optune physician second in education, is media inspire of critical By instill and engaging is designed and physicians journey. to prepare, guide GBM ecosystem, courage confidence, campaign Opt the support across on Optune the digital treatment caregivers For year. their and patients

the configuration as with as evolved more each these are the it improve Today, is to System MAXPOINT of use, array for Just product as patient. treatment is is is from plans. invention outcomes. system. the intensity to next-generation seek used allows create NovoTAL planning investments modalities further treatment component targeting optimize to optimal Array increase prescriber the designed we of array in an layout layout making treatment Optune precise to other provide intensity physical their therapy to TTFields ultimate we development of by their planning delivered the significant essential to to MAXPOINT individualized adapting tumor. our

This quarter, we evidence We array sharing compares advanced quarters. initiation program MAXPOINT MAXPOINT layouts of coming to program, dose in look forward an the the to metrics development volume data MAXPOINT-guided of generation the NovoTAL-guided from with which array layouts.

ongoing Europe now track this for ability a known Additionally, on higher, as in limited remain consistent FlexArray, release to the market a our have these the more deliver arrays year. next-generation We believe arrays, product journey and intensity represent MAXPOINT initiatives. to in and our the without commitment increasing development to our meaningful tumor bed product milestones highlight investment the meaningfully Both FlexArray development in heat.

we data TTFields tumor our we use response presented use cancer. the chemotherapy are is a GBM, durability the of partner, solid the together by TTFields abdomen. the below Lab, the rates EF-XX pilot notable of exploring with the survival of number improvements over of together from rate EF-XX for an EF-XX of XX.X both historical and XX% of torso duration months, and Zai and response in cancer gastric treatment We with prevalent X-year were rate the Beyond responses with shown in Gastric additional excited June, indications EF-XX response study. controls. data. demonstrated the In and deadly of objective both XX%. in of evaluated

pleased We with are signals EF-XX. very from generated the

therapies TTFields, a the with standard-of-care large together are clinical in benefit to randomized We continue eager study. exploring of potential

to and to future pipeline. our Looking the turning clinical

transformation. We are a period of potential entering

out clinical patients term. for could to XX-fold. near X Phase eligible LUNAR indications read the have We new read successful, the is out. increase of approximately readouts by III number to trials these TTFields poised If trial in our in pivotal next

non-small the is final LUNAR with cell docetaxel and of IV reminder, our patients' treatment XXXX. thoracic cancer. of completed evaluates lung in November of the PD-X the randomized enrollment Stage a study the and commenced program We second-line TTFields of first choice inhibitor for As LUNAR follow-up XX-month in or together use physician's

clinicians, final data investors week all parties, we Given a interested patients. ideal during for potential not investigators, feedback year from release the is the of pivotal received or trial recognize

QX remain to pivotal on moving XXXX. efforts visibility reason, announcement This that top our line convenience be for enrolled. collection from on follow-up data early XXXX To For clear, a data be operations for X-month ovarian clinical all in the the we -- audiences. ensure following our last made will release push and track study to INNOVATE-X, XX-month to and optimal announcement cancer, is data was recurrent patient an decision track.

we with reminder, continue earnings PANOVA-X XXXX the expectations. enrollment enroll line QX announced METIS during patients our a call. of in As completion and INNOVATE-X to of

to to The updates strengthen deliberate made of the second represent with We business quarter. and data new progress fundamentals to potential and plan second for patients releases inspired pending expansion pleased now are call We treating our the over financial in prospect the this steps our of by more I period into quarter Ashley excited near performance. in indications. large many remain run to through pass the will the term. and the

Ashley Cordova

Thank you, Bill.

adoption and performance so investments we this press from period Fields therapy in was me product brief few up as I dynamics X,XXX release was quarter will spoke and X% the to on call, and Tumor patients business, you second this another active in strong, seen Revenue clinical our profits particular, financials. Treating focus XX-Q the The the so earlier platform. on global broader with morning, financial June as Germany. have regarding the now in I gross Bill of core provide the know GBM with development XX. revenue, advance highlights trends strong funding on let a of

The strong and provide markets. in terms Optune. year, reminder, XX% we with reimbursement represent contracts many revenue a payers withheld the announced pricing approval patients agreement patients under As net of and we additional coverage we the established on will of to year, German in new These for with we foundation the payers began as pursue deny approval European payers approximately QX in negotiations the impacted lives Germany. active public criteria for last the for our that enable reached in listing. that largest formalized a stability price This price some covered DME a as

time, increase under collections over Gross collections grow to margin current second as more for revenue from Revenue was a realized price the sufficient execution the treated exceptional expect for contract and U.S., on second from quarter term. claims active NovoCure, business both the patients competency updated than in U.S. was is in patient In the benefit to benefiting denied from provided material the We in tailwind XX%. Germany more the and the the price operations average a at is are and headwinds core to the Strength of previously exchange. quarter. appealed offset an revenue volumes. and foreign U.S. processes

expenses initiatives. challenges by Zai while development marketing of optimize economic data an multiple functions, in offset year-over-year. We down activities in not due and the aggressively research, was X% capital, for geographical as million, expansion any supply pivotal alongside to second research expenses support as and of did increase per active increased material by revenues lower experience made product purchases commercial corporate-enabling Excluding XX% the dollars preclinical one inflation the month clinical our on was of our to totaled are from best in we patient work impact quarter. XX% cost period projects cost invested G&A more to our and chain, investing uses and second other than a the We from proactive approach $XX impact increase verticals. second readouts. early our per continued across to in expenses spending in marketing sales year-over-year cost decreased million we an quarter of year-over-year of revenues R&D our and broader XXXX. development of SG&A $XX reduction Lab, same quarter, from are

maximum was can the $XXX commercial quarter and $X pursue position stable. second or business We sheet. NovoCure's flexibility. we Our net ensures share million, with was our for million. growth loss investments we is our balance the $XX strong the opportunities and believe EBITDA financial $X.XX across is and cash million cash execution secure foundation the finished and period per in short-term Adjusted on with

in pivotal that fully launches continue will the potential We call the outcome to the the investing trials Asaf. pass are Tumor so Fields to leverage that, subsequent and With coming prepared quarters. platform aggressively we Treating in I of multiple will

Asaf Danziger

Thank you, Ashley.

our This of quarter, of advance most survival mission aggressive we of continued some in to forms cancer. the extending

adoption on external both our researchers. clinical therapy, Our of TTFields. see internal commercial support team focused for and mounting driving is from We

As their we pivotal science and the colleagues patients by treating the and several future. like next of we I the adoption in approach for readouts of year, in my near NovoCure over motivated TTFields. the to from studies advancing more would many determination thank prospect thousands passion are

as on bought who only begun move but had a our this house ENOUGH. journey, would includes RARE with skateboarder start In close, of family you job, he short GBM drive turn that, the mission prescribed engaged focus forward on documentary patient-forward we now years just was a like the know average and GBM Optune. brain We his was With new ENOUGH to our set watch minds. you joined day. DJ through and over of in where operator University keep become a community. all of I forward, have hope film. patient's and hearts had Medical reflections the all focused the story. free a for will To In rushed inspirational. an will Q&A. City. company the his diagnosis seizure and who made are and encourage I inspiring heartbreaking takes time Kansas I both recent that immense of DJ journey in candid our was treatment Head GBM Kansas and friends. XXXX, we to recently DJ's you Center, diagnosed to share Stewart RARE spent XXXX, to DJ strides DJ May to Cure, have the DJ DJ's cancer is in patients charity journey. in surrounded It and a by just and for your I is every call which like

Operator

Instructions]. [Operator

Our question Cory first from JPMorgan. with comes Kasimov

Cory Kasimov

I had for X you.

active gastric 'XX. the patient what believe number? primary you re-acceleration still on on a patients? side, clinical And to mind? next might First, growth expect the previously I side, just confident broader on commercial you cancer, for steps you and fiscal pivotal this year driver a Would looking the for any you guided that so, do X% like to for to it? comments second have just be breadth in Or be in of of Are X% yet you what in target half? HERX-positive the terms in secondly, to if the indication And then trial of strategy look do

William Doyle

today the world. has from saying virtually gathered This Bill. to all was team points just is by start I going our over

and to going it So Ashley will over question, of first to turn little bit MC, gastric Uri take to the about trial. going be and the I'm a then your talk to I'm

Ashley Cordova

Cory. Thanks, Perfect.

So active ex just growth was patient keep our year-over-year X%. to Germany,

markets Asian a have strong. U.S. focused, of in as clear and about, the we've recovery as X% patient providing on reiterate and not the we the drivers German to a sight other pace in And fluctuation in to of X%. commercial forward-looking talked enough are cover. just don't we European that active abrupt variety But It's volumes, line Germany remain of given we're

Cory Kasimov

side? And gastric great. that's then on Yes, the

Uri Weinberg

broad very incidents who anticipated received a in supporting region. first was fact strong with the which which TTFields applicability with On in for malignancy. yes, the always evidence gastric by efficacy, the therapy of side, has our the the rise Asia, But concomitantly of abdominal to so provided, disease especially the are course. another their designed study the high incidence, we of TTFields also that to study first-line And we're gastric have signal yet U.S. in And each cancer, beyond another encouraged the in was study patients unresectable XX

CheckMate-XXX III time. through the study we the anticipate Phase are fact certainly given of demonstrated in in the has this we the study, the seventh considering going checkpoint that incorporating in malignancy are design malignancy the study coming another Fields. sixth and having immune immune nivolumab study So inhibitors efficacy to And study, inhibitors we or checkpoint to the considering another seriously be involve Treating Tumor with

Operator

with Our Sandler. question Piper from comes Bednar Jason next

Jason Bednar

or like if much update. really possible I and data gets entirely wanted But LUNAR to sounds wanting make and the little to related it to to It push this headline about you different shift a a study? as can as all issues the just top in start the timing data And if sure is with top all Does blunt, just full drive data in attention data isn't place that be view not little to bit just I changed line talk timing the maybe set matter? been what months? now comparing arms in data of data, the that's the can you your several line the collection. for of really

William Doyle

Yes.

any So has to of just desirable. with thanks remarks any question. essentially the loud We for trial to Christmas heard prepared the I was and all this I what Year issues in and from that clear data slight do said issues. operational announcement our or not shift nothing constituents underline between that want New

this And purely QX. our the this early for is of into convenience to push so stakeholders

Jason Bednar

squeeze X here Okay. in a and follow-up. All right. guess Understood. I I'll

just an item. is First easy, quick housekeeping

that picture bigger patients Is on expand being claims patients size market can what's in the denied treated maybe previously coverage specifically And no recurrent by the it's second more can But think what's that in you way that therapy active what respect and those Just forward? being denied current reimbursement really that the was these the the to the here Cory's of longer coverage the that that revenue alluded can Germany. diagnosed in and patient It you now come those figure you just active for to? patients? I dynamics that impact are answered dynamics. newly the What like with payers? changed back the Germany rate and are patients in guess, the to the are just And covered referenced? the doesn't care, question. to best from a you sound it they some shifted on in going way Medicare Ashley, run on then fold, side, quarter? covered treated respect just with dynamics GBM then into Maybe

Ashley Cordova

I Yes. Jason. to because appreciate the everybody for takes. understand important question and these puts it is Thanks,

So with QX a I'll story, price remind U.S. everybody, price. the bit easier as start XXXX an to stable is you, we strength, I'll durable So of the anchored which right? and a

in price we quarter, the if and denied the about So the that strength the aged would tailwinds X/X it of to at U.S. in in put fundamental the X/X claims look to second versus previously business. I about and

it good a year, last I baseline. of which how is that's So out QX relative to put

-- and everybody we then reimbursement an if question So we because time for pathway on it's I'll Germany, new and a purposefully quarter we major as contracts be will significant other coverage and payers I'll markets we've in and back, the seek towards as know Germany Germany, more Medicare, in other to and indications. -- step oncologic spend important pricing for shift a in to foundation having strong this in DME that with this first now. enable listing pricing to are therapy just over understand. pursue me This this a reimbursement life-extending remind in stability is working European coverage is everybody If bit Similar and Germany take to established been let milestone Germany. years I we price a a important life-saving because

mandating official And importantly, the milestones we DME year, the payers. covered line quarter, with Germany. for payers March had EF-XX a the Optune end at reached with we QX way, Optune listing. we as this in agreement of coverage in terms the on contract issued then look last GBA have protocol. we with of largest German year, lives we if earlier And of So a the in announced XXXX, In directive for the that now price representing of formalized have XX% along the

therapy, withhold But we Optune listing, of our adjusted we the and criteria represent with of the extend a of of happened approval with the but portion stream background in DME those which that's result, context. course, the a they of our also if off established under under for the quarter, patients on as challenging for when started at mix were than value the So the newly We begin the the DME any we DME XX% not prior And can this criteria of specifically our not a second but were revenue both a the given approving start. that basis, year active and more, then of many and new our or line not recurring have and have review patients look take existing new With active to coverage EF-XX process updated duration active price payers lower protocol approval we compliance as patients ensure the terms. we this process. payers during But they coverage our many to have covered did a the patient a quarter Germany portion case-by-case confirming a protocol. in patient less listing, we patients had cleanly did material [indiscernible] match to new EF-XX patients prior therapy, business. in to did patient existing now what

ahead just But to be approved. quarter. which clear now, have background line looking So sight that's will the patients of we in the

policy. established DME have We

important from to quarters the just will that therapy given of a ensure We all have patient of play I kind established was will do compliance answer, several our we And expect starts of of over to through. have. over that each and I and payer but quarter the these. here the improve terms. with course walk We've Jason, time. this adjusted return mix the think long-winded patient duration revenue That But out processes will

So happy is additional questions any to take if necessary. clarification

Operator

Our comes Fraser Greg from next question Truist. with

Gregory Fraser

talk in think And in the be we can prices on you think would revenue basis, higher a net U.S., how going if helpful? the comments U.S. driving the you about Ashley, I that your you provide should on forward? month made the U.S.? about some could what's but per were color that global

Ashley Cordova

for Yes. question, the Again, Greg. thanks

from at U.S. is So strength in X primary in you claims. if we One look look the with price improvements XXXX about negotiations of price. baseline, in NPL if contract over versus coverage is the policies our and the the price, it additional buckets. remaining comes previously is anchor price, just And at comes X/X expanding QX X/X that players on the margin This denied in about strength from success U.S. which time. fundamental

is in will teams market ongoing say it high. of work operations related we and our aged the durable go So that aged those really X/X that revenue to performance the pipeline. after claims have is just and predictability of we those I I is access the as would really to U.S. not everybody X/X remind claims of continue

claims. And improvements would wouldn't ahead, on we look and think the when I not aged the so -- I enduring

Gregory Fraser

prescribe in you added talk you prescriptions seeing On patient Japan? you're headwinds Can to you there? group. trends about that declined, demand although And are number Understood. [indiscernible] Japan,

William Doyle

Pritesh. ahead, Go

Pritesh Shah

for Thank thanks Greg, you, the question. Bill.

that's we're the not new a cyclical say prescriptions nature So of would see within answer just how seeing disease headwinds. I any rare short the like through. GBM we flow is

Japan. based will data to business be efforts on ongoing the performance we Japan, the historical expect So and the our would of continue just our in there, stable in strength

Operator

with Wainwright. Our Bodnar next question comes from H.C. Emily

Emily Bodnar

one initial implement year to to order are in you on arrays with you your broadly? launch have want that guess, of looking what determine And you see that would more just to label see Optune? next-generation later kind this if launch potentially take the you to out to into to plan want Europe. the I for I that in what

William Doyle

to is therapeutic of Yes. Again, step the the can taking with through the final benefit. and incarnation device almost delivery the engineering a back device therapies, made Improvements incarnation. usability the never be first optimize

Europe of believe the earlier think the of we're we We the with help can medical our this the forward innings form really in in that in test for and major next ability form major You device This terms launch all What we're to of new patients. can is almost progression. arrays a of the later change factor year. step And we anticipate in technology, see the any systems. looking is to to is and our factor.

of capability So we our we our markets. have to update manufacturing all that serve so can all of

have we look for the are the to our to needed may patient to take we make that in surprising, surprise. can to surprises. we overcome user patients. do They're or that's right We anticipated. well we nature We see use going not instructions whatever something And of in don't but whatever for surprise for are always and instructions word factors manufacturing look any, people that's trained anticipate if And be. the sure this are use that the to bring to new therapy steps

overstate that from So experience development. the about we launch, excited plans I initial this as And I world. into how can't get am throughout soon the the our we'll as incorporate regulatory

Operator

Our Jason from next with Wittes Loop question comes Capital.

Jason Wittes

claims from? that claims. a you Was were mix some clarification permitted indication strength came Medicare? on where those first give that that denied Or denied could Medicare and Was and just of private? the of the all U.S. a Maybe

Ashley Cordova

our in largely That's but It's opportunity where it's the a is, mix, backlog. Medicare. largest

Jason Wittes

that mentioned, they the fair. inhibitors are not tumor. there's present it they checkpoint GBM. around And that been That's Is on as and the Great. barrier assumption? for the right have evidence Merck blood-brain inhibitors, trial with GBM checkpoint effective I take do for pass the you

William Doyle

checkpoint work just our you little Uri, the brain? with do want on inhibitors give background to in a

Uri Weinberg

course. of Yes,

the work remember, is through tumor. University response publication you other there been you against our of to is demonstrating which of make response evidence later of the of actually memory checkpoint external leads reaction also from one inflammatory the Tran that And with the demonstrated with adaptive immune David potentially the a this against achieve really as tumor showed could immune concomitant antitumor generation greater this has growing of So work of but Florida level Dr. throughout in-house collaborators, lab, to cancer. use how and cells JCI of immune inhibitors own response and the that treating

-- while control comparison incorporation of XX that was X-THE-TOP on effect the side, use intended evidence of about clinical increase and good was a coming time, more this than new on use study, survival the But XX.X to is but that EF-XX pembrolizumab showed the improvement. overall or study it median in of concomitant TTFields matched a there study a so median controls, the to we overall matched and where checkpoint population that's same the single-arm led months, inhibitors This the achieved X-THE-TOP is side. from is that single Optune to at scientific significant significant see in So a preliminary a preclinical a evidence survival. KEYTRUDA, one months already the more led indication concomitant less with on such

that second recurrent And it failed still DXX, MSD. for seems response results unfortunately in KEYNOTE across the potential clinical collaboration demonstrate clear with newly be significant immune very diagnosed barrier, the benefit clinical is coming So decreased, from leads immune the basis that a our GBM, with inhibitors planned penetration to to have it there this it's or the Merck a study. and and are true that in blood-brain efficacy checkpoint lower but

study. in was we first cell conducting cancer. forward III to this non-small The pivotal Phase looking are lung And

Jason Wittes

you I patients Great. for Or at that heard kind potential think screening that That gastric that also, did that at to And expand indications mentioned of criteria? upon look for lead you differences. the future was Is for you when genetic were may I trial looked something that very you what could the correctly TTF? helpful.

Asaf Danziger

in we the demonstrating certain you level despite in could included that to front, to unmethylated, different this potentially in to is the gastric at At And study. XX different in opportunity alterations patient the centers MGMT of of design down subpopulations of that characterize U.S. small really newly the into the Neuro-oncology study Advances it's broad published the or was we data did response see more variations immune in take EF-XX when population. variations more comes benefit we nature and the increase could we genetic study very the GBM. immune that because and to genetic patient collecting improved recall, try especially course, it. are in So not fact how we a the if patients. planning subpopulations, And on the study effective and And itself. same look this population. this key preliminary to patient the for promoter, independent and about number of actually from correlate whether single-arm the do And there the and in see to was in from genetic always in patients the recently response patient came it see in as several one population, well to And setting also outcome it it date, of tumor post-approval project time, older that GBM diagnosed investigators TTFields methylated and broke alterations trying are younger by TTFields, EF-XX, population with

other are outcome this identification biomarkers and but and again, support effective the population -- applying in itself to even from is of the TTFields. will that the trying that findings So generate patient broader treatment population, always could improve find the we

Operator

comes Our from Kumar Evercore. Vijay next question with

Ashley Cordova

back hear we Operator, can can you. we right. to think queue. go to the don't back we Michelle, All I perhaps queue. go Vijay, the

Operator

are There to over call the for Bill further remarks. turn back questions. any I'd Doyle like further to no

William Doyle

to I the morning. join everyone this my the management have extend and like quarter. team when also in. like speak We're Asaf myself, hard very NovoCure line on work we Michelle. for who thank pleased I'd this with us to I I'd and entire Asaf know and I say dedication. appreciate for the thanks for joining to the the dialed Thanks, employees progress

Treating take action will And in in to on to months. exciting quarters, The progress coming updating NovoCure, from to we grow. our This an and a have look pivotal time of Thanks trials. you the number forward again. late-stage business is behind Fields fundamentals for the at the data continues coming and we to strengthen deliberate science prepare continue the of We our Tumor future.

Operator

program. concludes This the

may a You now day. disconnect. great Everyone, have

NovoCure Limited (NVCR) 28 Jul 222022 Q2 Earnings call transcript